# A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

> **NCT02028455** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 167 (actual)

## Conditions studied

- CD19+ Acute Leukemia

## Interventions

- **BIOLOGICAL:** Patient Derived CD19 specific CAR T cells also expressing an EGFRt

## Key facts

- **NCT ID:** NCT02028455
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-02-11
- **Primary completion:** 2021-08-10
- **Final completion:** 2036-07
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02028455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02028455, "A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02028455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*